Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of oral SAL0112 in adults with type 2 diabetes mellitus
CTR20242666Phase 2Active
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fogliptin benzoate in type 2 diabetes mellitus (T2DM), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Started Sep 2024; status: active.
02
Drugs
fogliptin benzoate
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20242666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242666.